Portage Biotech Inc

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients with refractory NSCLC and melanoma Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients with refractory NSCLC and melanoma

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Study will evaluate PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC) Study will evaluate PORT-2 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC)

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

The consensus price target hints at a 268.4% upside potential for Portage Biotech Inc. (PRTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 268%

After losing some value lately, a hammer chart pattern has been formed for Portage Biotech Inc. (PRTG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over Portage Biotech Inc. (PRTG), Here's Why It's a 'Buy' Now

--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Over the Next two Years--

Portage Biotech Provides Research and Development Update

WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company's management team will be presenting at the following upcoming investor conferences:

Portage Biotech to Present at Upcoming Investor Conferences

--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024--

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board

Portage Biotech Announces Leadership Updates

The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets--

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3.  The platform was acquired.

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stock Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stock

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its mechanism of action Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its mechanism of action

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Late-breaking preclinical data generated by Stimunity suggests that packaging cGAMP STING activator in a virus-like particle leads to activation of tumor-specific T cells Late-breaking preclinical data generated by Stimunity suggests that packaging cGAMP STING activator in a virus-like particle leads to activation of tumor-specific T cells

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Preclinical data will be presented in a late-breaking abstract session Preclinical data will be presented in a late-breaking abstract session

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022 Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Leading biopharma executive Brian Wiley joins as Chief Business Officer

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

WESTPORT, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company will participate in three investor conferences during the month of January.

Portage Biotech Announces Participation in January 2022 Investor Conferences

WESTPORT, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the quarter ended September 30, 2021 (the “second quarter of Fiscal 2022”).

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. Dr. Walters will give an overview of Portage's pipeline and status of current programs, including the company's lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

WESTPORT, Conn., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented by Intensity Therapeutics during the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and the Connective Tissue Oncology Society (CTOS) Annual Meeting. Data from the Phase 2 IT-01 trial shows that Intensity's lead asset, INT230-6 (PORT-1) is well tolerated with direct tumor-killing effects, both as a monotherapy and in combination with the approved checkpoint inhibitors pembrolizumab and ipilimumab. Highlights from the presentations are included below.

Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics' INT230-6 (PORT-1) at November Scientific Conferences

News for Portage Biotech Inc Stock (PRTG)